Product Name: Y3
Product Number: PE-01AEU90
| Size: | 200 µg | Price: | 22.00 | |
| 1 mg | $US | 45.00 |
Peptide Name: Y3
Peptide Production Method: Solid-phase peptide synthesis
Peptide Sequence: SIYNFEKL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1012.2 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Production Method: Solid-phase peptide synthesis
Peptide Sequence: SIYNFEKL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1012.2 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC).
References
[1] Florian Wiede, Benjamin J. Shields, Sock Hui Chew, Konstantinos Kyparissoudis, Catherine van Vliet, Sandra Galic, Michel L. Tremblay, Sarah M. Russell, Dale I. Godfrey, Tony Tiganis. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. Clin Invest. 2011;121(12):4758–4774. PMCID: PMC3226006; doi:10.1172/JCI59492
[2] O'Sullivan JA, Zloza A, Kohlhapp FJ, Moore TV, Lacek AT, Dulin NO, Guevara-Patiño JA. Priming with very low-affinity peptide ligands gives rise to CD8+ T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression. Cancer Immunol Immunother. 2011 November; 60(11): 1543–1551. PMCID: PMC3327162; doi: 10.1007/s00262-011-1043-1
[1] Florian Wiede, Benjamin J. Shields, Sock Hui Chew, Konstantinos Kyparissoudis, Catherine van Vliet, Sandra Galic, Michel L. Tremblay, Sarah M. Russell, Dale I. Godfrey, Tony Tiganis. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. Clin Invest. 2011;121(12):4758–4774. PMCID: PMC3226006; doi:10.1172/JCI59492
[2] O'Sullivan JA, Zloza A, Kohlhapp FJ, Moore TV, Lacek AT, Dulin NO, Guevara-Patiño JA. Priming with very low-affinity peptide ligands gives rise to CD8+ T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression. Cancer Immunol Immunother. 2011 November; 60(11): 1543–1551. PMCID: PMC3327162; doi: 10.1007/s00262-011-1043-1
© Kinexus Bioinformatics Corporation 2017